Evidence map›Paper›PMID 26330748›Full record

ArticleMolecular vision2015

Role of 5'TG3'-interacting factors (TGIFs) in Vorinostat (HDAC inhibitor)-mediated Corneal Fibrosis Inhibition.

Ajay Sharma, Nishant R Sinha, Saad Siddiqui, Rajiv R Mohan

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Role of epigenetics in corneal health and disease.Progress in retinal and eye research · 2025
    Review
  5. Article
  6. MiR-424/TGIF2-Mediated Pro-Fibrogenic Responses in Oral Submucous Fibrosis.International journal of molecular sciences · 2023
    Article
  7. Review
  8. Corneal stromal repair and regeneration.Progress in retinal and eye research · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Role ofMolecular vision · 2020
    Article
  15. Corneal injury: Clinical and molecular aspects.Experimental eye research · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ajay SharmaHarry S. Truman Memorial Veteran Hospital, Columbia, MO ; Veterinary Medicine and Surgery, University of Missouri, Columbia, MO.
Nishant R SinhaVeterinary Medicine and Surgery, University of Missouri, Columbia, MO.
Saad SiddiquiVeterinary Medicine and Surgery, University of Missouri, Columbia, MO.
Rajiv R MohanHarry S. Truman Memorial Veteran Hospital, Columbia, MO ; Mason Eye Institute, School of Medicine, Columbia, MO ; Veterinary Medicine and Surgery, University of Missouri, Columbia, MO.
University of Missouri · US

Funding

Gene Therapy in the CorneaR01EY017294 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2007 to 2018
$4.3M
Targeted Gene Therapy and Nanomedicine Approaches to Treat Corneal DiseasesI01BX000357 · VA · HARRY S. TRUMAN MEMORIAL VA HOSPITAL · PI Rajiv Ravindra Mohan · 2009 to 2026
–
BLRD VA I01 BX000357NEI NIH HHS R01 EY017294NEI NIH HHS R01EY017294
6 · The paper itself

Abstract

purposeWe have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC) inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ). The 5'TG3'-interacting factors (TGIFs) are transcriptional repressors of TGFβ1 signaling via the Smad pathway. The present study was designed to explore the expression of TGIFs in human corneal fibroblasts and to investigate their role in mediating the antifibrotic effect of vorinostat.

methodsHuman corneal fibroblast cultures were generated from donor corneas. RNA isolation, cDNA preparation, and PCR were performed to detect the presence of TGIF1 and TGIF2 transcripts. The cultures were exposed to vorinostat (2.5 µM) to test its effect on TGIF mRNA and protein levels using qPCR and immunoblotting. Myofibroblast formation was induced with TGFβ1 (5 ng/ml) treatment under serum-free conditions. The changes in fibrosis parameters were quantified by measuring fibrosis marker α-smooth muscle actin (αSMA) mRNA and protein levels with qPCR, immunostaining, and immunoblotting. Smad2/3/4 and TGIF knockdowns were performed using pre-validated RNAi/siRNAs and a commercially available transfection reagent.

resultsHuman corneal fibroblasts showed the expression of TGIF1 and TGIF2. Vorinostat (2.5 µM) caused a 2.8-3.3-fold increase in TGIF1 and TGIF2 mRNA levels and a 1.4-1.8-fold increase in TGIF1 and TGIF2 protein levels. Vorinostat treatment also caused a significant increase in acetylhistone H3 and acetylhistone H4. Vorinostat-induced increases in TGIF1 and TGIF2 were accompanied by a concurrent decrease in corneal fibrosis, as indicated by a decrease in αSMA mRNA by 83±7.7% and protein levels by 97±5%. The RNAi-mediated knockdown of Smad2, Smad3, and Smad4 markedly attenuated TGFβ1-evoked transdifferentiation of fibroblasts to myofibroblasts. The siRNA-mediated knockdown of TGIF1 and TGIF2 neutralized vorinostat-evoked decreases in αSMA mRNA by 31%-45% and protein levels by 12%-23%.

conclusionsHuman corneal fibroblasts demonstrate the expression of TGIF1 and TGIF2 transcription factors. These transcriptional repressors are critical, at least partially, in mediating the antifibrotic effect of vorinostat in the cornea.

Indexed as

Cells, CulturedCell TransdifferentiationCorneaCorneal DiseasesCorneal InjuriesFibroblastsFibrosisGene Knockdown TechniquesHistone Deacetylase InhibitorsHomeodomain ProteinsHumansHydroxamic AcidsModels, BiologicalMyofibroblastsRepressor ProteinsRNA InterferenceHistone Deacetylase InhibitorsHomeodomain ProteinsHydroxamic AcidsRepressor ProteinsSmad ProteinsTGIF1 protein, humanTGIF2 protein, humanVorinostat

Identifiers

PMID26330748
PMCPMC4551282
OpenAlexW1954550383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.